Role of 5α-Reductase Inhibitors in Benign Prostatic Diseases

February 2012 in “ Prostate cancer and prostatic diseases ”

Faris Azzouni, James L. Mohler

5α-reductase inhibitors finasteride dutasteride dihydrotestosterone DHT Propecia Avodart

TLDR 5α-reductase inhibitors help shrink the prostate, improve urinary symptoms, and may reduce prostate cancer risk.

The document reviewed the role of 5α-reductase inhibitors, such as finasteride and dutasteride, in treating benign prostatic diseases. These inhibitors effectively reduced dihydrotestosterone (DHT) levels, leading to decreased prostate size and improved urinary symptoms in men with benign prostatic hyperplasia (BPH). They also lowered prostate-specific antigen (PSA) levels, aiding in prostate health monitoring. Clinical trials showed that these medications could reduce the risk of acute urinary retention and the need for surgical intervention. Additionally, finasteride and dutasteride reduced prostatic vascularity, with finasteride significantly decreasing perioperative blood loss during transurethral resection of the prostate (TURP) and managing hematuria associated with BPH. Dutasteride also showed potential in reducing prostate cancer risk.

View this study on nature.com →

Discuss this study in the Community →

Research cited in this study

11 / 11 results

research SRD5A3 Is Required for Converting Polyprenol to Dolichol and Is Mutated in a Congenital Glycosylation Disorder

260 citations, July 2010 in “Cell”

Mutations in the SRD5A3 gene cause a new type of glycosylation disorder by blocking the production of a molecule necessary for protein glycosylation.

A Randomized Placebo-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Finasteride for Male Chronic Pelvic Pain Syndrome (Category IIIA Chronic Nonbacterial Prostatitis)

research A Randomized Placebo-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Finasteride for Male Chronic Pelvic Pain Syndrome (Category IIIA Chronic Nonbacterial Prostatitis)

127 citations, May 2004 in “PubMed”

Finasteride may help some male chronic pelvic pain patients, but more research needed.

research Marked Suppression of Dihydrotestosterone in Men with Benign Prostatic Hyperplasia by Dutasteride, a Dual 5α-Reductase Inhibitor

408 citations, May 2004 in “The Journal of clinical endocrinology and metabolism/Journal of clinical endocrinology & metabolism”

Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.

A Prospective, 1-Year Trial Using Saw Palmetto Versus Finasteride in the Treatment of Category III Prostatitis/Chronic Pelvic Pain Syndrome

research A Prospective, 1-Year Trial Using Saw Palmetto Versus Finasteride in the Treatment of Category III Prostatitis/Chronic Pelvic Pain Syndrome

105 citations, January 2004 in “The Journal of Urology”

Finasteride improves chronic pelvic pain, saw palmetto doesn't.

research The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia

1707 citations, December 2003 in “The New England Journal of Medicine”

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.

research Clinical Application of 5α-Reductase Inhibitors

46 citations, March 2001 in “Journal of endocrinological investigation”

5α-reductase inhibitors, like finasteride and dutasteride, effectively treat BPH, male baldness, and hirsutism, with potential for acne and prostate cancer prevention.

research Effect of Finasteride and/or Terazosin on Serum PSA: Results of VA Cooperative Study #359

41 citations, June 1999 in “The Prostate”

Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.

research Effects of Finasteride in Patients with Inflammatory Chronic Pelvic Pain Syndrome: A Double-Blind, Placebo-Controlled, Pilot Study

65 citations, March 1999 in “Urology”

Finasteride didn't significantly improve ICPPS symptoms, more research needed.

The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment Among Men with Benign Prostatic Hyperplasia

research The Effect of Finasteride on the Risk of Acute Urinary Retention and the Need for Surgical Treatment Among Men with Benign Prostatic Hyperplasia

1054 citations, February 1998 in “The New England Journal of Medicine”

Finasteride reduces urinary issues and surgery need in men with enlarged prostates by over 50%.

research The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia

728 citations, August 1996 in “The New England Journal of Medicine”

Terazosin and finasteride effectively treat BPH, but combining them adds no extra benefit.

research The Effect of Finasteride in Men with Benign Prostatic Hyperplasia

1040 citations, October 1992 in “The New England Journal of Medicine”

Finasteride effectively treats BPH but may increase sexual dysfunction risk.

Related Research

4 / 4 results

research Comparative Effect of Finasteride and Dutasteride on Chromogranin A Levels

1 citations, November 2010 in “Anticancer Research”

research Comparison of Clinical Trials with Finasteride and Dutasteride

20 citations, January 2004 in “PubMed”

research Effect of MK-386, a Novel Inhibitor of Type 1 5 Alpha-Reductase, Alone and in Combination with Finasteride, on Serum Dihydrotestosterone Concentrations in Men

7 citations, August 1996 in “The Journal of Clinical Endocrinology and Metabolism”

research Effect of Finasteride, a 5 Alpha-Reductase Inhibitor, on Serum Gonadotropins in Normal Men

9 citations, August 1992 in “The Journal of Clinical Endocrinology and Metabolism”